Non-cirrhotic portal hypertension in HIV mono-infected patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1512-1519

  Jackson, Belinda D ^a   Doyle, Joseph S ^a,b,c   Hoy, Jennifer F ^a   Roberts, Stuart K ^a   Colman, John ^a   Hellard, Margaret E ^a,c   Sasadeusz, Joseph J ^a,b   Iser, David M ^a,d  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

Anti retroviral therapy; Human immunodeficiency virus; Liver disease; Portal hypertension

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASCITES; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; LIVER VEIN OBSTRUCTION; POLYMERASE CHAIN REACTION; PORTAL HYPERTENSION; PRIORITY JOURNAL;

EID: 84865372266     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07148.x     Document Type: Article

References (40)

1. Ingiliz P, Valantin MA, Duvivier C etal. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49: 436-42.
2. Friedrich-Rust M, Ong M, Martens S etal. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
3. Moreno S, Garcia-Samaniego J, Moreno A etal. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J. Viral Hepat. 2009; 16: 249-58.
4. Vergara S, Macias J, Rivero A etal. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis. 2007; 45: 969-74.
5. Chang PE, Miquel R, Blanco JL etal. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am. J. Gastroenterol. 2009; 104: 1707-14.
6. Maida I, Garcia-Gasco P, Sotgiu G etal. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir. Ther. 2008; 13: 103-7.
7. Panos G, Farouk L, Stebbing J etal. Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIV. J. Acquir. Immune Defic. Syndr. 2009; 52: 525-7.
8. Vispo E, Moreno A, Maida I etal. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24: 1171-6.
9. Arey B, Markow M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007; 21: 1066-8.
10. Bihl F, Janssens F, Boehlen F, Rubbia-Brandt L, Hadengue A, Spahr L. Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol. 2010; 10: 6.
11. Dinh MH, Stosor V, Rao SM, Miller FH, Green RM. Cryptogenic liver disease in HIV-seropositive men. HIV Med. 2009; 10: 447-53.
12. Mendizabal M, Craviotto S, Chen T, Silva MO, Reddy KR. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann. Hepatol. 2009; 8: 390-5.
13. Saifee S, Joelson D, Braude J etal. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin. Gastroenterol. Hepatol. 2008; 6: 1167-9.
14. Vispo E, Maida I, Barreiro P, Moreno V, Soriano V. Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients. HIV Clin. Trials 2008; 9: 440-4.
15. Tateo M, Sebagh M, Bralet M etal. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl. 2008; 14: 1194-8.
16. Nayak N, Ramalingaswami V. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly. Arch. Pathol. 1969; 87: 359-69.
17. Kameda H, Yamazaki K, Imai F, Sugiura M, Nakashima T, Okuda K. Obliterative portal venopathy: a comparison study of 184 cases of extrahepatic portal obstruction and 469 cases of idiopathic portal hypertension. J. Gastroenterol. Hepatol. 1986; 1: 139-49.
18. Schiano T, Kotler D, Ferran E, Fiel M. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am. J. Gastroenterol. 2007; 102: 2536-40.
19. Reshamwala P, Kleiner D, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44: 7-14.
20. Garvey L, Thomson E, Lloyd J, Cooke G, Goldin R, Main J. Response to Mallet etal., "Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients." AIDS 2007; 21: 1494-5.
21. Mallet VP, Blanchard V, Verkarre A etal. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187-92.
22. Cotte L, Bénet T, Billioud C etal. The role of nucleoside and nucleotide analogues in nodular regenrative hyperplasia in HIV-infected patients: a case control study. J. Hepatol. 2011; 54: 589-496.
23. Kovari H, Ledergerber B, Peter U etal. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin. Infect. Dis. 2009; 49: 626-35.
24. Maida I, Soriano V, Castellares C etal. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin. Trials 2006; 7: 246-50.
25. Cesari M, Schiavini M, Marchetti G etal. Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. AIDS Patient Care STDS 2010; 24(11): 697-703.
26. Mallet V, Varthaman A, Lasne D etal. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23: 1511-18.
27. Cazals-Hatem D, Hillaire S, Rudler M etal. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J. Hepatol. 2011; 54: 455-61.
28. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J. Gastroenterol. Hepatol. 1999; 14: 618-33.
29. Tuyama A, Hong F, Saiman Y etal. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52: 612-22.
30. Ingiliz P, Benhamou Y. Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications? J. HIV Ther. 2009; 14: 3-7.
31. Ingiliz P, Valantin MA, Duvivier C etal. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49(2): 436-42.
32. Jolles S, Kinloch-de Loes S, Johnson MA, Janossy G. Primary HIV-1 infection: a new medical emergency. BMJ 1996; 312: 1243-4.
33. BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for anti-retroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 108S92.
34. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment. Pharmacol. Ther. 2007; 25: 1135-51.
35. Yarchoan R, Mitsuya H, Thomas RV etal. In vivo activity against HIV and favorable toxicity profile of 2′, 3′-dideoxyinosine. Science 1989; 245: 412-15.
36. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357: 1412-14.
37. Schiano TD, Uriel A, Dieterich DT, Fiel MI. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch. 2011; 458: 231-5.
38. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52: 1143-55.
39. Francque S, Verrijken A, Mertens I etal. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur. J. Gastroentrol. Hepatol. 2010; 22: 1449-57.
40. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J. Gastroenterol. 2008; 14: 185-92.